FORBES-TATE

Lobbying for SYDNEXIS · Biopharmaceutical company focused on ophthalmic treatments.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $60,000.00 income · posted Jan 18, 2026

Lobbying activity 1

Health Issues

Issues related to ophthalmic treatments.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem